Marlborough Pharmaceuticals Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Marlborough Pharmaceuticals Limited - overview
Established
2013
Location
Basildon, -, UK
Primary Industry
Business Support Services
About
Marlborough Pharmaceuticals Limited is a specialized pharmaceutical company focused on the commercialization and revitalization of established medicines across various therapeutic areas, including cardiology, endocrinology, neurology, and oncology. Founded in 2013, Marlborough Pharmaceuticals Limited is dedicated to the life cycle management of pharmaceutical products, emphasizing a strategy for revitalizing established treatments. The company operates from its headquarters in the United Kingdom and has not undergone significant pivots or changes in its business operations since its inception. Information regarding founders or previous companies is not available.
Marlborough Pharmaceuticals specializes in life cycle management, focusing on revitalizing established medicines across therapeutic areas such as cardiovascular, endocrinology, neurology, and oncology. Their primary products include Inderal®, Tenormin®, Bonviva®, and Synacthen®, aimed at improving patient outcomes through innovative delivery mechanisms and effective therapeutic solutions. The company caters to a diverse clientele, including healthcare providers, patients, and pharmaceutical partners across markets in Europe and Eastern Europe. Marlborough Pharmaceuticals generates revenue through a varied transaction structure involving partnerships with healthcare providers, wholesalers, and direct-to-consumer sales.
The company engages in business-to-business transactions with pharmaceutical distributors and healthcare institutions, positioning products effectively within the market. Revenue is driven by flagship products like Zestril® and Valium®, through pricing agreements and contracts with clients, supporting a sustainable revenue pipeline from both established and new product sales. Currently, specific details about upcoming products or expansion plans are not available. Recent funding initiatives may be allocated towards enhancing product development and exploring new market opportunities, but further information on targeted markets or regions for expansion is not provided.
Primary Industry
Business Support Services
Sub Industries
Business Support Services
Website
www.marlborough-pharma.co.uk
Total Amount Raised
Subscriber access only
Marlborough Pharmaceuticals Limited - financials
| Fiscal Year Ended | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 |
|---|---|---|---|---|---|---|
| Revenue (USD) | 17,072,523 | 16,113,636 | 15,424,000 | - | - | - |
| % Revenue Growth (YoY) | - | (5.6%) | (4.3%) | - | - | - |
| EBITDA (USD) | 8,598,322 | 8,073,818 | 7,736,000 | - | - | - |
| Operating Income (USD) | 8,598,322 | 8,073,818 | 7,719,000 | - | - | - |
| Operating Margin | 50.4% | 50.1% | 50.0% | - | - | - |
| % EBITDA Margin | 50.4% | 50.1% | 50.2% | - | - | - |
| NET Income (USD) | 7,057,342 | 6,580,285 | 7,767,000 | - | - | - |
| % Net Margin | 41.3% | 40.8% | 50.4% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.